8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

January 12, 2015

(Date of the earliest event reported)

Simulations Plus, Inc.

(Exact name of registrant as specified in its charter)

California	001-32046	95-4595609
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

42505 10^th Street West, Lancaster, California 93534-7059

(Address of principal executive offices) (Zip Code)

661-723-7723

Registrant's telephone number, including area code

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[  ] Soliciting material pursuant to Rule 14z-12 under Exchange Act (17 CFR 240.14a-12)

[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under Exchange Act (17 CFR 240.14d-2(b))

[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under Exchange Act (17 CFR 240.13e-4(c))

Item 7.01  Regulation FD Disclosure

On January 12, 2015, Simulations Plus, Inc., a California corporation, attended the Sidoti & Company Emerging Growth Institutional Investor Forum in New York, NY. Simulations Plus presented and held one-on-one meetings with investors. The PowerPoint slides, which were used for discussion at the Conference, are attached herein as exhibit 99.2 to this Current Report on Form 8-K.

Item 8.01  Other Events

On January 12, 2015, Simulations Plus, Inc., a California corporation (the "Company"), issued a press release announcing financial results for its first quarter of fiscal year 2015 ended November 30, 2014 and announcing that it will hold its quarterly investor conference call on Wednesday January 14, 2015. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The information set forth in this Current Report on Form 8-K shall not be deemed an admission as to the materiality of any information in this report on Current Report on Form 8-K that is required to be disclosed solely to satisfy the requirements of Regulation FD.

This report on Form 8-K (the "Report"), including the disclosures set forth herein, contains certain forward-looking statements that involve substantial risks and uncertainties. When used herein, the terms "anticipates," "expects," "estimates," "believes" and similar expressions, as they relate to us or our management, are intended to identify such forward-looking statements.

Forward-looking statements in this Report or hereafter, including in other publicly available documents filed with the Securities and Exchange Commission (the "Commission"), reports to the stockholders of Simulations Plus, Inc., a California corporation (the "Company" or "us," "our" or "we") and other publicly available statements issued or released by us involve known and unknown risks, uncertainties and other factors which could cause our actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. Such future results are based upon management's best estimates based upon current conditions and the most recent results of operations. These risks include, but are not limited to, the risks set forth herein and in such other documents filed with the Commission, each of which could adversely affect our business and the accuracy of the forward-looking statements contained herein. Our actual results, performance or achievements may differ materially from those expressed or implied by such forward-looking statements.

Item 9.01  Financial Statements and Exhibits

(d) Exhibits

99.1	Press release issued on January 12, 2015.
99.2	PowerPoint presentation used at the Sidoti & Company Emerging Growth Institutional Investor Forum in New York, NY held on January 12, 2015.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	SIMULATIONS PLUS, INC.
Dated: January 12, 2015	By:	/s/ John R. Kneisel
		John R. Kneisel Chief Financial Officer

3

EX-99.1

Exhibit 99.1

Simulations Plus Reports First Quarter FY2015 Financial Results

Final report of first quarter financial results after Cognigen merger; net revenues up 54%; gross profit increased 41%

LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, today reported financial results for its first quarter of fiscal year 2015 ended November 30, 2014 (1QFY15).

1QFY15 highlights compared with 1QFY14:

· Simulations Plus, Inc. acquired Cognigen Corporation through a merger that closed on September 2, 2014. The numbers presented herein represent the consolidated financial results.

· Net revenues increased 54.7%, or $1.4 million, to $4.1million from $2.6 million. $1.1 million of the increase was from Cognigen consulting revenue.

· Gross profit increased 40.9% to $3.1 million from $2.2 million. $600,000 of this increase due to Cognigen revenue.

· SG&A increased by $1.0 million of which $410,000 was one-time charges related to the merger, $538,000 was related to operating expenses of the new subsidiary, and $72,000 was from increased commission and selling expenses.

· Income before taxes and net income decreased approximately 22% due mainly to the effect of one-time charges for the Cognigen merger. As a result, diluted earnings per share decreased $0.01 to $0.03 from $0.04 per share. Without the one-time charges, diluted earnings per share would have been approximately $0.05 per share up 58%.

John Kneisel, chief financial officer of Simulations Plus, said: “This quarter, Simulations Plus continued its sustained growth in software revenues, as well as closing the acquisition with Cognigen. This quarter’s net income was substantially affected by approximately $410,000 in one-time fees and expenses that were incurred for the acquisition of Cognigen. The integration plan for financial reporting with Cognigen has gone smoothly and we continue to integrate our operational and financial processes. We are in a strong financial position with cash balances in excess of $6 million.”

Ted Grasela, newly appointed president of the combined Simulations Plus and Cognigen company, added: “I have been impressed with the quality and commitment of the scientists at Simulations Plus and the loyalty and enthusiasm of our client base. We have already seen significant opportunities for collaboration and synergies in terms of our marketing and sales efforts. I am excited about the enhanced scientific capabilities we are offering as a result of the merger. I look forward to offering new and expanded consulting services to clients of both companies. In addition, software development activities have continued apace and exciting opportunities are emerging as our scientists gain cross-disciplinary experience during our collaborations.”

1

John DiBella, vice president for marketing and sales for Simulations Plus, said: “1Q15 was very strong for software sales, as the number of units licensed saw a 20% increase compared to 1Q14. This was largely driven by 23 new organizations, or new departments at existing organizations, now utilizing our technology. Included among these new licenses were orders from several commercial companies in Asia, a territory we continue to penetrate. We are pleased by the level of interest seen in our new MembranePlus™ software, and the feedback received from the first round of evaluations has been positive. We are also close to releasing the next version of our flagship GastroPlus™ software, and with its ability to simulate the distribution of large molecules in humans and animals, we anticipate it will help us expand into the robust biopharmaceuticals market. Education remains a key focus for us in 2015, as we have scheduled workshops in the U.S., Europe, and Asia to allow us to train more scientists on the applications of our technology.”

Walt Woltosz, chairman and chief executive officer of Simulations Plus, added: “Fiscal year 2015 is off to a very good start with this record first quarter. Ted is ably managing the combined company, enabling me to increase my focus on products, services, and business development. I am particularly excited about two new products under development for use in the aerospace and healthcare industries. These products use our artificial neural network ensemble modeling engine and we intend to pursue customers and funding to develop customized tools and applications.”

The Company has announced an investor conference call that will be webcast live at 1:15 p.m. PST/4:15 p.m. EST on Wednesday, January 14, 2015, which may be joined by registering at the following website: https://attendee.gotowebinar.com/register/8868645760194807041. On registering, you will receive a confirmation e-mail with instructions for joining the call. Please dial in five to ten minutes prior to the scheduled start time. For listen-only mode, you may dial (646) 307-1708, and enter access code 274-738-985.

About Simulations Plus, Inc.

Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation and modeling software which is licensed to and used in the conduct of drug research by major pharmaceutical, biotechnology, agrochemical, and food industry companies worldwide. Simulations Plus also recently acquired Cognigen Corporation of Buffalo, NY, adding to our offerings top quality modeling and simulations using clinical trial data, as well as more than doubling our staff from 30 to 65, adding nearly 50% to revenues, and expecting to increase earnings in the coming fiscal year that began September 1. The Company is headquartered in Southern California and trades on the NASDAQ Capital Market under the symbol “SLP.” Cognigen Corp is located in Buffalo, New York. For more information, visit our Web site at www.simulations-plus.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect” and “anticipate” mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports as filed with the U.S. Securities and Exchange Commission.

2

SIMULATIONS PLUS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

			As of
	(Unaudited)		(Audited)
	November 30,		August 31,
	2014		2014
ASSETS
Current assets
Cash and cash equivalents	$	5,791,177	$	8,614,929
Accounts receivable, net of allowance for doubtful accounts of $0		2,995,959		1,708,158
Revenues in excess of billings		734,503		158,914
Prepaid income taxes		626,128		748,359
Prepaid expenses and other current assets		264,093		188,160
Deferred income taxes		274,548		114,846
Total current assets		10,686,408		11,533,366
Long-term assets
Capitalized computer software development costs, net of accumulated amortization of $6,822,573 and $5,993,404		3,736,980		3,452,541
Property and equipment, net		518,378		95,242
Intellectual property, net of accumulated amortization of $345,625 and $193,750		5,729,375		5,881,250
Other intangible assets net of accumulated amortization of $36,875		1,613,125		–
Goodwill		4,789,248		–
Other assets		34,083		18,445
Total assets	$	27,107,597	$	20,980,844
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities
Accounts payable	$	153,211	$	130,547
Accrued payroll and other expenses		672,734		340,709
Accrued bonuses to officer		24,000		120,000
Other current liabilities		19,859		19,859
Current portion - Contracts payable		750,000		750,000
Billings in excess of revenues		129,725		–
Deferred revenue		34,879		30,370
Total current liabilities		1,784,408		1,391,485
Long-term liabilities
Deferred income taxes		3,230,446		2,375,874
Payments due under Contracts payable		3,604,405		1,750,000
Other long-term liabilities		23,169		28,134
Total liabilities		8,642,428		5,545,493
Commitments and contingencies
Shareholders' equity
Preferred stock, $0.001 par value 10,000,000 shares authorized no shares issued and outstanding		–		–
Common stock, $0.001 par value 50,000,000 shares authorized 16,841,114 and 16,073,894 shares issued and outstanding		5,312		4,821
Additional paid-in capital		9,427,906		6,085,427
Retained earnings		9,031,951		9,345,103
Total shareholders' equity		18,465,169		15,435,351
Total liabilities and shareholders' equity	$	27,107,597	$	20,980,844

3

SIMULATIONS PLUS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

	For the three months ended
	(Unaudited)
	November 30,
	2014			2013
Net revenues	$	4,086,192		$	2,641,000
Cost of sales		997,734			448,420
Gross profit		3,088,458			2,192,580
Operating expenses
Selling, general, and administrative		2,079,169			1,071,091
Research and development		259,912			162,116
Total operating expenses		2,339,081			1,233,207
Income from operations		749,377			959,373
Other income (expense)
Interest income		4,592			9,026
Miscellaneous income		–			–
Loss on currency exchange		(7,790	)		23,709
Total other income (expense)		(3,198	)		32,735
Income from continuing operations before provision for income taxes		746,179			992,108
Provision for income taxes		(217,275	)		(306,953	)
Net Income	$	528,904		$	685,155
Earnings per share
Basic	$	0.03		$	0.04
Diluted	$	0.03		$	0.04
Weighted-average common shares outstanding
Basic		16,830,319			16,049,707
Diluted		17,097,858			16,366,720

Contacts

Simulations Plus Investor Relations
Ms. Renee Bouche, 661-723-7723
renee@simulations-plus.com
or
Hayden IR
Mr. Cameron Donahue, 651-653-1854
cameron@haydenir.com

Source: Simulations Plus, Inc.

View this news release online at:
http://www.businesswire.com/news/home/20150112005415/en

4

EX-99.2

Exhibit 99.2

Copyright (c) 2015 Simulations Plus, Inc. 1 Simulations Plus, Inc. and Cognigen Corp. (NASDAQ:SLP ) Investor Meetings New York City January 12 - 13, 2015

Copyright (c) 2015 Simulations Plus, Inc. 2 With the exception of historical information, the matters discussed in this presentation are forward - looking statements that involve a number of risks and uncertainties. The actual results of the Company could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: continuing demand for the Company’s products, competitive factors, the Company’s ability to finance future growth, the Company’s ability to produce and market new products in a timely fashion, the Company’s ability to continue to attract and retain skilled personnel, and the Company’s ability to sustain or improve current levels of productivity. Further information on the Company’s risk factors is contained in the Company’s quarterly and annual reports and filed with the Securities and Exchange Commission. Safe Harbor Statement

Copyright (c) 2015 Simulations Plus, Inc. 3 • Major software provider for pharmaceutical research and development • Consulting services for problem drugs and formulations • Expertise and software tools span from earliest drug discovery through clinical trials and beyond patent life to supporting generic companies • New applications being explored in aerospace and general healthcare • Acquisition of Cognigen Corp. in September 2014 more than doubles workforce, expected to add $4 - 5 million to revenues in FY15 – first combined fiscal quarter just completed on November 30 • Consolidated revenues up 54% over last year’s first fiscal quarter; gross profit increased 41% • Currently distributing dividend of $0.20/year per share ($0.05/quarter) , subject to board approval each quarter Simulations Plus, Inc. Overview

Copyright (c) 2015 Simulations Plus, Inc. 4 Simulations Plus, Inc. Overview of Products and Services 4 N H O OH O CH 3 CH 3 CH 3 ADMET Predictor ™ GastroPlus ™ Population PK/PD Modeling & Simulations Regulatory Submission MedChem Studio ™ MedChem Designer™ DDDPlus ™ MembranePlus ™ Consulting Services and Collaborations Cognigen

Copyright (c) 2015 Simulations Plus, Inc. 5 The Science Behind the Software What happens when I swallow a pill? GI Tract Chemical Degradation Dissolution

Copyright (c) 2015 Simulations Plus, Inc. 6 The Science Behind the Software What happens after the medicine is absorbed?

Copyright (c) 2015 Simulations Plus, Inc. PBPK Modeling and Simulation is Becoming More Common in Regulatory Submissions 7 Figure 1. The number of PBPK applications contained in IND/NDA submissions or developed by US FDA reviewers from 2008 to 2012. Huang, Shiew - Mei, et al, The utility of modeling and simulation in drug development and regulatory review, J Clin Pharm 2013 DOI 10.1002/jps.23570

Copyright (c) 2015 Simulations Plus, Inc. 8 • FDA Center for Food Safety and Applied Nutrition (modeling of toxicity endpoints) • FDA Office of Testing and Research (mechanistic absorption and IVIVCs) • NIEHS National Toxicology Program (screening of the Tox21 database using QSAR and PBPK modeling) • FDA Office of Generic Drugs (ocular absorption) • Recently awarded $200,000/year contract for up to 3 years • Numerous client - funded projects to enhance software platform for specialty purposes Strong Relationships With Regulators (and Pharma Companies) Driving Applications

Copyright (c) 2015 Simulations Plus, Inc. 9 • Provide modeling & simulation support for Pharma and Biotech companies • Primary focus on data from clinical studies • 30 - 40 drugs per year; >100 different compounds over the last 5 years • Track record of successful regulatory submissions utilizing pharmacometric modeling & simulation • >25 regulatory submissions over the last 5 years alone • Dose selection and justification • Well - established quality management system and successful client audit record • 44 successful client audits over the last 10 years Cognigen Division - Overview

Copyright (c) 2015 Simulations Plus, Inc. 10 • Worked with 22 clients on 62 projects covering 38 different compounds • Average length of current client relationship is 6 years ranging from 1 - 14 years • 6 new clients • 6 regulatory submissions • Typically work on 4 to 8 submissions per year Cognigen Division - Calendar Year 2014

Copyright (c) 2015 Simulations Plus, Inc. 11 • Significant investment in IT infrastructure and workflow processes • Recently upgraded computer systems, implemented automated offsite backup storage, and installed green technology to reduce computer cooling costs • KIWI ™ - proprietary software provides access to validated private cloud for model development; licensed to 2 organizations to date Cognigen Division Infrastructure

Copyright (c) 2015 Simulations Plus, Inc. 12 • Cognigen • Penetration of clinical pharmacology departments to provide more detailed mechanistic modeling for clinical trial data analysis – regulatory agencies want this • Expand marketing effort for KIWI ™ • Expand marketing effort for modeling & simulation services • Piggyback onto Simulations Plus’ presence at national and international scientific meetings Simulations Plus, Inc. Additional Growth Opportunities

Copyright (c) 2015 Simulations Plus, Inc. 13 • Of 2,500 companies registered with FDA, both foreign and domestic, we have ~10% penetration with Simulations Plus products • http://www.fda.gov/Drugs/NewsEvents/ucm339912.htm • Continued enhancement of current software products to expand application space • Dermal and improved oral cavity dosing modules in GastroPlus™ • Addition of biologics (antibodies) to GastroPlus • Addition of large animals to GastroPlus • MembranePlus ™ • New software product to simulate in vitro permeability experiments released in 1Q15; Webinar held December 2, 2014 – nearly 100 attendees Simulations Plus, Inc. Additional Growth Opportunities, cont’d.

Copyright (c) 2015 Simulations Plus, Inc. 14 • AEROModeler ™ • Application of our artificial neural network ensemble (ANNE) technology to predict aerodynamic force coefficients for missiles at arbitrary Mach number and angle of attack - much faster than conventional methods ‒ Presented at our first aerospace conference in June 2014 ‒ Will be presenting at two aerospace conferences in 2015 • MRIModeler ™ • Application of our ANNE technology to analysis of magnetic resonance imaging (MRI) data to classify patients as healthy or likely to experience various disease states ‒ Presented at our first MRI conference in September 2014 Simulations Plus, Inc. Additional Growth Opportunities, cont’d.

Copyright (c) 2015 Simulations Plus, Inc. 15 • Conferences/scientific meetings continue to be primary source of leads • During FY14, we participated in 48 scientific meetings and conferences in the US, Europe, and Asia with 30 scientific posters and presentations • In 4Q14, we presented at our first aerospace conference • In 1Q15 we presented at our first MRI conference • Trainings and workshops • Conducted 21 onsite training courses at client sites in FY14 • Conducted training workshops in Germany, New Jersey, Japan, and Korea • 2015 workshops scheduled for US, Europe, and Asia Simulations Plus, Inc. Marketing and Sales Program

Copyright (c) 2015 Simulations Plus, Inc. 16 • Strategic digital marketing initiatives • Hosted 7 webinars on our new software updates and applications - over 1100 registrations • Active updates of LinkedIn, Facebook, and Twitter accounts help with outreach programs • We believe fundamental industry shift continues • Western GastroPlus User Group now has over 560 members on LinkedIn • Japan GastroPlus User Group continues to add new members • Added 75 new customers during FY14 (includes new companies, as well as new departments within existing large customers) – added 23 new customers in 1QFY15 ‒ New companies in US, Europe, India, Japan, China, and Korea ‒ New divisions at the US EPA and Chinese FDA Simulations Plus, Inc. Marketing and Sales Program

Copyright (c) 2015 Simulations Plus, Inc. 17 FY15.1 Sales By Region Europe 19% North America 56% Asia 25% South America <1% Japan = 50% India = 15% China = 28% Korea = 7%

Copyright (c) 2015 Simulations Plus, Inc. 18 New Customers By Quarter 10 11 9 9 14 17 12 14 15 21 13 10 18 18 16 9 15 22 20 18 Q1 Q2 Q3 Q4 2010 2011 2012 2013 2014 2015 23

Copyright (c) 2015 Simulations Plus, Inc. 19 • FQY15.1 compared to FQY14.1 • Sales increased by $1.5 million to $4.1 million from $2.6 million ‒ Cognigen revenues were $1.1 million ‒ Simulation Plus revenue increased $310,000 or 11.7% in FQY15.1 vs. FQY 14.1 • Cost of revenues increase by $537,000. ‒ $521,000 of this increase was salaries at Cognigen. Representing 46% of revenues ‒ Simulations Plus cost of revenues decrease as a percentage of revenues by 1.8% which is mainly attributable to the effect of the May 2014 TSRL agreement • Gross profit increased $896,000 to $3.1 million in FQY15.1 from $2.2 million in FQY14.1. ‒ $600,000 of the increase is from Cognigen FQY15.1 Highlights Fiscal Quarter Ended 11/30/14

Copyright (c) 2015 Simulations Plus, Inc. 20 • FQY15.1 compared to FQY14.1( Con’t ) • Consolidated Gross margin decreased to 75.6% from 82.5% ‒ Cognigen gross margin for the quarter was 52.9% ‒ Simulations Plus margin for the quarter was 84.3% up from 82.5% the prior year • SG&A increased $1.0 million to $2.1 million from $1.1 million the prior year ‒ $538,000 of the increase is from Cognigen ‒ During the current fiscal quarter we incurred approximately $410,000 in one - time costs associated with the Cognigen acquisition, which was charged to SG&A. ‒ Simulations Plus SG&A increased $72,000 due to increases in commissions paid to our Asian dealers, increased travel for training programs and trade shows, and increase d salary and benefit costs. ‒ As a percent of revenues, SG&A increased to 51% in FQY15.1 from 40% in FQY14.1 ‒ The expenses of the Cognigen acquisition represented approximately 10% of the increase. FQY15.1 Highlights Fiscal Quarter Ended 11/30/14

Copyright (c) 2015 Simulations Plus, Inc. 21 • FQY15.1 compared to FQY14.1( Con’t ) • R&D expense increased 60.3% to $260,000 from $162,000 the prior year ‒ This increase resulted from a higher mix of expensed R&D in FQY15.1 compared to FQY14.1 • Other income(expense) decrease by $36K in FQY15.1 vs. FQY14.1, the result of foreign currency fluctuations. • Net income decreased by $156,000 or 22.8% to $529,000 in FQY15.1 from $685,000 in FY14.1 ‒ Without the one - time costs associated with the Cognigen acquisition, net income would have been approximately $290,000 higher in this fiscal period and would have resulted in a 19.6% increase for the quarter FQY15.1 Highlights Fiscal Quarter Ended 11/30/14

Copyright (c) 2015 Simulations Plus, Inc. 22 • FQY15.1 compared to FQY14.1( Con’t ) • Diluted earnings per share was $ 0.03 in FQY15.1, a decrease of $ 0.01 from $ 0.04 in FQY14.1 • Without one - time charges, diluted earnings per share would have been approximately $0.05 per share, up 58% • Cash dividends totaling $0.05/share were distributed during this fiscal quarter FQY15.1 Highlights Fiscal Quarter Ended 11/30/14

Copyright (c) 2015 Simulations Plus, Inc. 23 Income Statement FQY15.1 Versus QY14.1 ($ millions) FQY15.1 FQY14.1 Net sales 4.086 2.641 Gross profit 3.088 2.193 Gross profit margin 75.6% 83.0% SG&A 2.079 1.071 R&D 0.260 0.162 Total operating expenses 2.339 1.233 Income from operations 0.749 0.959 Other income(expense) (.003) 0.033 Income from operations before income taxes 0.746 0.992 Net income 0.529 0.685 Diluted earnings per share 0.031 0.043

Copyright (c) 2015 Simulations Plus, Inc. 24 Income Statement FQY15.1 by division ($ millions) SLP Cognigen Eliminations FQY15.1 Net sales 2.951 1.135 0.00 4.086 Gross profit 2.488 0.600 0.00 3.088 Gross profit margin 84.3% 52.9% 0.00 75.6% SG&A 1.541 0.537 0.00 2.079 R&D 0.260 0.000 0.00 0.260 Total operating expenses 1.801 0.537 0.00 2.339 Income from operations 0.686 0.063 0.00 0.749 Other income(expense) (.003) .000 0.00 (.003) Income from operations before income taxes 0.683 0.063 0.00 0.746 Net income 0.489 0.040 0.00 0.529

Copyright (c) 2015 Simulations Plus, Inc. 25 Selected Balance Sheet Items ($ millions) November 30, 2014 November 30, 2013 Cash and cash equivalents* $5.791 $10.555 Cash per share 0.34 0.64 Total current assets 10.686 13.136 Total assets 27.108 16.405 Total current liabilities 1.784 0.791 Total liabilities 8.642 2.054 Current ratio 5.99 16.6 Shareholders’ equity 18.465 14.350 Total liabilities and shareholders’ equity 27.108 16.405 Shareholders’ equity per diluted share 1.080 0.877 * Cash today is ~ $6.4 million

Copyright (c) 2015 Simulations Plus, Inc. 26 Revenues by Quarter (pro forma prior to 2012) $1.4 $1.8 $2.0 $1.1 $1.7 $2.2 $2.3 $1.3 $2.1 $2.6 $2.6 $1.4 $2.2 $2.8 $2.8 $1.6 $2.3 $3.1 $3.1 $1.6 $2.6 $3.1 $2.0 Q1 Q2 Q3 Q4 2009 2010 2011 2012 2013 2014 2015 $3.7 $4.01 Included $1.135 million from Cognigen

Copyright (c) 2015 Simulations Plus, Inc. 27 $1.24 $1.53 $1.75 $0.71 $1.45 $1.93 $1.97 $1.07 $1.70 $2.21 $2.21 $1.12 $1.90 $2.39 $2.33 $1.32 $1.90 $2.62 $2.64 $1.26 $2.19 $2.59 $1.54 Q1 Q2 Q3 Q4 2009 2010 2011 2012 2013 2014 2015 Gross Profit by Fiscal Quarter (pro forma prior to 2012 ) $3.5 $3.09

Copyright (c) 2015 Simulations Plus, Inc. 28 EBITDA by Fiscal Quarter $0.55 $0.73 $0.93 $0.20 $0.73 $1.28 $1.23 $0.36 $1.00 $1.48 $1.48 $0.27 $1.23 $1.38 $1.48 $0.58 $1.09 $1.76 $1.73 $0.44 $1.20 $1.35 $0.67 1.45 Q1 Q2 Q3 Q4 2009 2010 2011 2012 2013 2014 2015 $2.1

Copyright (c) 2015 Simulations Plus, Inc. 29 Net Income by Quarter (pro forma prior to 2012) $ 0.33 $ 0.47 $ 0.53 $ 0.17 $ 0.44 $ 0.85 $ 0.74 $ 0.21 $ 0.56 $ 0.91 $ 1.05 $ 0.17 $ 0.76 $ 0.84 $ 0.87 $ 0.35 $ 0.59 $ 1.06 $ 0.99 $ 0.24 $ 0.69 $ 0.81 $ 1.31 $ 0.22 $ 0.53 Q1 Q2 Q3 Q4 2009 2010 2011 2012 2013 2014 2015

Copyright (c) 2015 Simulations Plus, Inc. 31 • For FQY15.1 - Revenues and earnings continued seven - year - plus profitable trend - Cognigen acquisition increases revenues, expands offerings into clinical pharmacology - Earnings for quarter lower due to one - time charges associated with the Cognigen acquisition • Continuing to grow - 54.7% revenue growth seen in first combined fiscal quarter - 35 new staff added with acquisition of Cognigen • Strong cash position – returning cash to shareholders - Cash dividends totaling approximately $9 million have been distributed, yet cash remains at $6.4 million as of today • Aggressive marketing and sales activities - Continue intensive conference/trade show/workshop schedule - Workshops scheduled for North America, Europe, and Asia in 2015 - Expand Cognigen marketing and sales activities Summary

Copyright (c) 2015 Simulations Plus, Inc. 32 Q&A